CN110198739A - 一种pd-l1抗体药物组合物及其用途 - Google Patents

一种pd-l1抗体药物组合物及其用途 Download PDF

Info

Publication number
CN110198739A
CN110198739A CN201880007923.6A CN201880007923A CN110198739A CN 110198739 A CN110198739 A CN 110198739A CN 201880007923 A CN201880007923 A CN 201880007923A CN 110198739 A CN110198739 A CN 110198739A
Authority
CN
China
Prior art keywords
seq
antibody
pharmaceutical composition
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880007923.6A
Other languages
English (en)
Other versions
CN110198739B (zh
Inventor
颜贞
杨健健
颜晓丹
吴珊
刘洵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Suncadia Biopharmaceuticals Co Ltd
Shanghai Shengdi Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN110198739A publication Critical patent/CN110198739A/zh
Application granted granted Critical
Publication of CN110198739B publication Critical patent/CN110198739B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明提供了一种PD‑L1抗体药物组合物及其用途。具体而言，本发明提供了一种药物组合物，其包含琥珀酸盐缓冲剂中的PD‑L1抗体或其抗原结合片段。除此之外，该药物组合物还可含有糖和非离子表面活性剂。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN201880007923.6A 2017-05-16 2018-05-15 一种pd-l1抗体药物组合物及其用途 Active CN110198739B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017103416807 2017-05-16
CN201710341680 2017-05-16
PCT/CN2018/086866 WO2018210230A1 (zh) 2017-05-16 2018-05-15 一种pd-l1抗体药物组合物及其用途

Publications (2)

Publication Number Publication Date
CN110198739A true CN110198739A (zh) 2019-09-03
CN110198739B CN110198739B (zh) 2023-04-04

Family

ID=64273337

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880007923.6A Active CN110198739B (zh) 2017-05-16 2018-05-15 一种pd-l1抗体药物组合物及其用途

Country Status (13)

Country Link
US (1) US11654194B2 (zh)
EP (1) EP3626266A4 (zh)
JP (1) JP7263256B6 (zh)
KR (1) KR102623679B1 (zh)
CN (1) CN110198739B (zh)
AU (1) AU2018267843A1 (zh)
BR (1) BR112019023846A2 (zh)
CA (1) CA3062487A1 (zh)
MX (1) MX2019013751A (zh)
MY (1) MY195465A (zh)
RU (1) RU2766590C2 (zh)
TW (1) TWI734916B (zh)
WO (1) WO2018210230A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112618482A (zh) * 2019-09-24 2021-04-09 江苏恒瑞医药股份有限公司 新型蛋白制剂

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018009064A8 (pt) * 2015-11-17 2019-02-26 Jiangsu Hengrui Medicine Co anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo
WO2020108497A1 (zh) * 2018-11-29 2020-06-04 和铂医药（香港）有限公司 一种抗pd-l1抗体制剂
BR112021013415A2 (pt) * 2019-01-07 2021-12-28 Univ Jefferson Proteínas de fusão multifuncionais e usos das mesmas
CN112125975B (zh) * 2019-06-25 2024-03-01 上海翰森生物医药科技有限公司 Pd-l1和cd47双特异性融合蛋白及其医药用途
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
WO2021025140A1 (ja) 2019-08-08 2021-02-11 小野薬品工業株式会社 二重特異性タンパク質
CA3227991A1 (en) * 2021-07-29 2023-02-02 Shanghai Junshi Biosciences Co., Ltd. Anti-pd-1 antibody pharmaceutical composition and use thereof
TW202333789A (zh) * 2022-01-05 2023-09-01 大陸商上海邁晉生物醫藥科技有限公司 一種包含抗ＦＸＩ／ＦＸＩａ抗體的醫藥組成物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245640A (zh) * 2008-12-09 2011-11-16 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU716785B2 (en) * 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
DE69810481T2 (de) * 1997-06-13 2003-09-25 Genentech Inc Stabilisierte antikörperformulierung
PT1441589E (pt) * 2001-11-08 2012-08-13 Abbott Biotherapeutics Corp Formulação farmacêutica líquida estável de anticorpos igg
SI1907424T1 (sl) * 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
LT2691112T (lt) 2011-03-31 2018-07-25 Merck Sharp & Dohme Corp. Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
SG11201602283UA (en) 2013-09-27 2016-04-28 Genentech Inc Anti-pdl1 antibody formulations
ES2710211T3 (es) 2014-02-04 2019-04-23 Pfizer Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer
BR112018005349A2 (zh) 2015-09-28 2018-10-09 Suzhou Suncadia Biopharmaceuticals Co., Ltd. An anti-PD-1 antibody preparation and its application in medicine
BR112018009064A8 (pt) 2015-11-17 2019-02-26 Jiangsu Hengrui Medicine Co anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo
CN107198773A (zh) 2017-06-08 2017-09-26 上海药明生物技术有限公司 重组抗pd‑l1全人单克隆抗体的液体制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245640A (zh) * 2008-12-09 2011-11-16 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112618482A (zh) * 2019-09-24 2021-04-09 江苏恒瑞医药股份有限公司 新型蛋白制剂

Also Published As

Publication number Publication date
RU2019139093A3 (zh) 2021-08-10
CN110198739B (zh) 2023-04-04
JP7263256B2 (ja) 2023-04-24
KR20200005650A (ko) 2020-01-15
KR102623679B1 (ko) 2024-01-11
RU2766590C2 (ru) 2022-03-15
AU2018267843A1 (en) 2019-12-12
BR112019023846A2 (pt) 2020-06-09
RU2019139093A (ru) 2021-06-16
EP3626266A1 (en) 2020-03-25
JP7263256B6 (ja) 2023-07-24
MX2019013751A (es) 2020-01-15
JP2020520939A (ja) 2020-07-16
TW201900211A (zh) 2019-01-01
TWI734916B (zh) 2021-08-01
US20200069800A1 (en) 2020-03-05
CA3062487A1 (en) 2018-11-22
MY195465A (en) 2023-01-25
US11654194B2 (en) 2023-05-23
EP3626266A4 (en) 2021-04-07
WO2018210230A1 (zh) 2018-11-22
WO2018210230A8 (zh) 2019-09-26

Similar Documents

Publication Publication Date Title
JP7263256B2 (ja) Ｐｄ－ｌ１抗体医薬組成物およびその使用
Elgundi et al. The state-of-play and future of antibody therapeutics
JP7436477B2 (ja) ＴＧＦ－β受容体融合タンパク質医薬組成物およびその使用
CN107614529B (zh) Pd-l1抗体、其抗原结合片段及其医药用途
WO2018095428A1 (zh) Cd47抗体、其抗原结合片段及其医药用途
CN110538321B (zh) 一种cd47抗体药物组合物及其用途
CN109843927A (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
CN110366560A (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
JP2021510533A (ja) 抗４−１ｂｂ抗体、その抗原結合フラグメント、およびその医学的使用
US20210009706A1 (en) Anti-CD27 Antibody, Antigen-binding Fragment Thereof, and Medical Use Thereof
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
CN111375059A (zh) 一种抗gitr抗体药物组合物及其用途
JP2020532279A (ja) 抗ｇｉｔｒ抗体、その抗原結合性断片、およびその医薬用途
CN112543647B (zh) 一种tim3抗体药物组合物及其用途
JP2020532491A (ja) Ｐｃｓｋ−９抗体を含む医薬組成物及びその使用
JP2023543461A (ja) インターロイキン－１８結合タンパク質と血清アルブミンに対する抗原結合断片とを含む組換え融合タンパク質ならびにその組成物および使用
AU2019388931A1 (en) CD40 antibody pharmaceutical composition and use thereof
CA3225970A1 (en) Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application
CA3196933A1 (en) Anti-cd3 antibody and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013346

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230921

Address after: 201203 floor 2-3, building 14, No. 3728, Jinke Road, pilot Free Trade Zone, Pudong New Area, Shanghai

Patentee after: SHANGHAI SHENGDI PHARMACEUTICAL Co.,Ltd.

Patentee after: SUZHOU SUNCADIA BIOPHARMACEUTICALS Co.,Ltd.

Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.